After the June 19, 2007 announcement of the company under the name ALAPIS SOCIETE ANONYME, HOLDING INDUSTRIAL AND COMMERCIAL PHARMACEUTICALS, CHEMICAL AND BIOLOGICAL PRODUCTS with the distinctive title ALAPIS SA (hereafter the company) regarding the decisions of the Extraordinary Shareholders Meeting, which took place on Monday June 18, 2007, the company announces that its Board of Directors, at the said shareholders Meeting, invited all shareholders who hold a 5% participation, directly or indirectly, of the company's share capital and participate also at the company's management, such as the members of the Board or its senior officers, to state their intention as regards their participation to the company as it is known at the Shareholders Meeting and if they will hold it until the end of the share capital increase period and for six (6) months following the starting trading day of the new shares. The company also announces that Mr. Lavrentis Lavrentiades, Chairman of the BoD and holder of 52.58% participation of the company's share capital, stated during the said Extraordinary Shareholders Meeting the following, according to article 289 of the Athens Exchange Rules and Regulations, and we quote:
"Presently I hold 52.58% of the company's share capital. It is my intention to maintain a 20% stake at the company's share capital after the completion of the share capital increase. To this end I estimate presumably to sell part of the shares currently owned and/or sell rights of this share capital increase, a decision that is contingent upon market conditions or other unexpected events, which may occur".